Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 30 entries
Sorted by: Best Match Show Resources per page
An evaluation of intravenous vitamin k for warfarin reversal: are guideline recommendations being followed?.

Hospital pharmacy

Rivosecchi RM, Garavaglia J, Kane-Gill SL.
PMID: 25684796
Hosp Pharm. 2015 Jan;50(1):18-24. doi: 10.1310/hpj5001-018.

BACKGROUND: Vitamin K antagonists (eg, warfarin) remain the mainstay of anticoagulation therapy in the United States, with over 22 million prescriptions being filled annually. Unfortunately, warfarin therapy is difficult to manage and increases bleeding risk. The 2012 American College...

Cite
Rivosecchi RM, Garavaglia J, Kane-Gill SL. An evaluation of intravenous vitamin k for warfarin reversal: are guideline recommendations being followed?. Hosp Pharm. 2015;50(1):18-24doi: 10.1310/hpj5001-018.
Rivosecchi, R. M., Garavaglia, J., & Kane-Gill, S. L. (2015). An evaluation of intravenous vitamin k for warfarin reversal: are guideline recommendations being followed?. Hospital pharmacy, 50(1), 18-24. https://doi.org/10.1310/hpj5001-018
Rivosecchi, Ryan M, et al. "An evaluation of intravenous vitamin k for warfarin reversal: are guideline recommendations being followed?." Hospital pharmacy vol. 50,1 (2015): 18-24. doi: https://doi.org/10.1310/hpj5001-018
Rivosecchi RM, Garavaglia J, Kane-Gill SL. An evaluation of intravenous vitamin k for warfarin reversal: are guideline recommendations being followed?. Hosp Pharm. 2015 Jan;50(1):18-24. doi: 10.1310/hpj5001-018. PMID: 25684796; PMCID: PMC4321424.
Copy Download .nbib Format: NLM
Screening and Management of Delirium in Critically Ill Patients.

Hospital pharmacy

Farina N, Smithburger P, Kane-Gill S.
PMID: 26715799
Hosp Pharm. 2015 Sep;50(8):667-71. doi: 10.1310/hpj5008-667. Epub 2015 Sep 16.

Delirium is highly prevalent in the critically ill population and has been associated with numerous negative outcomes including increased mortality. The presentation of a delirious patient in the intensive care unit (ICU) is characterized by a fluctuating cognitive status...

Cite
Farina N, Smithburger P, Kane-Gill S. Screening and Management of Delirium in Critically Ill Patients. Hosp Pharm. 2015;50(8):667-71doi: 10.1310/hpj5008-667.
Farina, N., Smithburger, P., & Kane-Gill, S. (2015). Screening and Management of Delirium in Critically Ill Patients. Hospital pharmacy, 50(8), 667-71. https://doi.org/10.1310/hpj5008-667
Farina, Nicholas, et al. "Screening and Management of Delirium in Critically Ill Patients." Hospital pharmacy vol. 50,8 (2015): 667-71. doi: https://doi.org/10.1310/hpj5008-667
Farina N, Smithburger P, Kane-Gill S. Screening and Management of Delirium in Critically Ill Patients. Hosp Pharm. 2015 Sep;50(8):667-71. doi: 10.1310/hpj5008-667. Epub 2015 Sep 16. PMID: 26715799; PMCID: PMC4686470.
Copy Download .nbib Format: NLM
Feasibility of an Academic Detailing Intervention to Support Deprescribing in the Nursing Home.

Journal of the American Medical Directors Association

Pruskowski JA, Kane-Gill SL, Kavalieratos D, Wilson BK, Arnold RM, Handler SM.
PMID: 34324872
J Am Med Dir Assoc. 2021 Nov;22(11):2398-2400.e4. doi: 10.1016/j.jamda.2021.06.025. Epub 2021 Jul 27.

No abstract available.

Cite
Pruskowski JA, Kane-Gill SL, Kavalieratos D, et al. Feasibility of an Academic Detailing Intervention to Support Deprescribing in the Nursing Home. J Am Med Dir Assoc. 2021;22(11):2398-2400.e4doi: 10.1016/j.jamda.2021.06.025.
Pruskowski, J. A., Kane-Gill, S. L., Kavalieratos, D., Wilson, B. K., Arnold, R. M., & Handler, S. M. (2021). Feasibility of an Academic Detailing Intervention to Support Deprescribing in the Nursing Home. Journal of the American Medical Directors Association, 22(11), 2398-2400.e4. https://doi.org/10.1016/j.jamda.2021.06.025
Pruskowski, Jennifer A, et al. "Feasibility of an Academic Detailing Intervention to Support Deprescribing in the Nursing Home." Journal of the American Medical Directors Association vol. 22,11 (2021): 2398-2400.e4. doi: https://doi.org/10.1016/j.jamda.2021.06.025
Pruskowski JA, Kane-Gill SL, Kavalieratos D, Wilson BK, Arnold RM, Handler SM. Feasibility of an Academic Detailing Intervention to Support Deprescribing in the Nursing Home. J Am Med Dir Assoc. 2021 Nov;22(11):2398-2400.e4. doi: 10.1016/j.jamda.2021.06.025. Epub 2021 Jul 27. PMID: 34324872.
Copy Download .nbib Format: NLM
Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study.

American journal of nephrology

Barreto EF, Schreier DJ, May HP, Mara KC, Chamberlain AM, Kashani KB, Piche SL, Wi CI, Kane-Gill SL, Smith VT, Rule AD.
PMID: 34727542
Am J Nephrol. 2021;52(10):817-826. doi: 10.1159/000519375. Epub 2021 Nov 02.

INTRODUCTION: Acute kidney injury (AKI) affects 20% of hospitalized patients and worsens outcomes. To limit complications, post-discharge follow-up and kidney function testing are advised. The objective of this study was to evaluate the frequency of follow-up after discharge among...

Cite
Barreto EF, Schreier DJ, May HP, et al. Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study. Am J Nephrol. 2021;52(10):817-826doi: 10.1159/000519375.
Barreto, E. F., Schreier, D. J., May, H. P., Mara, K. C., Chamberlain, A. M., Kashani, K. B., Piche, S. L., Wi, C. I., Kane-Gill, S. L., Smith, V. T., Rule, A. D. (2021). Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study. American journal of nephrology, 52(10), 817-826. https://doi.org/10.1159/000519375
Barreto, Erin F, et al. "Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study." American journal of nephrology vol. 52,10 (2021): 817-826. doi: https://doi.org/10.1159/000519375
Barreto EF, Schreier DJ, May HP, Mara KC, Chamberlain AM, Kashani KB, Piche SL, Wi CI, Kane-Gill SL, Smith VT, Rule AD. Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study. Am J Nephrol. 2021;52(10):817-826. doi: 10.1159/000519375. Epub 2021 Nov 02. PMID: 34727542; PMCID: PMC8665070.
Copy Download .nbib Format: NLM
A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

Cardiovascular drugs and therapy

Patel NM, Stottlemyer BA, Gray MP, Boyce RD, Kane-Gill SL.
PMID: 33599896
Cardiovasc Drugs Ther. 2021 Feb 18; doi: 10.1007/s10557-021-07157-3. Epub 2021 Feb 18.

PURPOSE: Between 2012 and 2017, the FDA approved 29 therapies for a cardiovascular disease (CVD) indication. Due to the limited literature on patient safety outcomes for recently approved CVD medications, this study investigated adverse drug reports (ADRs) reported in...

Cite
Patel NM, Stottlemyer BA, Gray MP, et al. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Cardiovasc Drugs Ther. 2021;doi: 10.1007/s10557-021-07157-3.
Patel, N. M., Stottlemyer, B. A., Gray, M. P., Boyce, R. D., & Kane-Gill, S. L. (2021). A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Cardiovascular drugs and therapy, . https://doi.org/10.1007/s10557-021-07157-3
Patel, Niti M, et al. "A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database." Cardiovascular drugs and therapy vol. (2021). doi: https://doi.org/10.1007/s10557-021-07157-3
Patel NM, Stottlemyer BA, Gray MP, Boyce RD, Kane-Gill SL. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Cardiovasc Drugs Ther. 2021 Feb 18; doi: 10.1007/s10557-021-07157-3. Epub 2021 Feb 18. PMID: 33599896.
Copy Download .nbib Format: NLM
Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.

Journal of critical care

Buckley MS, Komerdelj IA, D'Alessio PA, Rangan P, Agarwal SK, Tinta NC, Martinez BK, Ziadat DS, Yerondopoulos MJ, Kobic E, Kane-Gill SL.
PMID: 34768175
J Crit Care. 2022 Feb;67:134-140. doi: 10.1016/j.jcrc.2021.10.018. Epub 2021 Nov 09.

PURPOSE: The risk of acute kidney injury (AKI) associated with concomitant vancomycin and piperacillin/tazobactam in the intensive care unit (ICU) remains controversial. The aim of this study was to compare the AKI incidence associated with concomitant vancomycin and piperacillin/tazobactam...

Cite
Buckley MS, Komerdelj IA, D'Alessio PA, et al. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study. J Crit Care. 2021;67:134-140doi: 10.1016/j.jcrc.2021.10.018.
Buckley, M. S., Komerdelj, I. A., D'Alessio, P. A., Rangan, P., Agarwal, S. K., Tinta, N. C., Martinez, B. K., Ziadat, D. S., Yerondopoulos, M. J., Kobic, E., & Kane-Gill, S. L. (2022). Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study. Journal of critical care, 67134-140. https://doi.org/10.1016/j.jcrc.2021.10.018
Buckley, Mitchell S, et al. "Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study." Journal of critical care vol. 67 (2022): 134-140. doi: https://doi.org/10.1016/j.jcrc.2021.10.018
Buckley MS, Komerdelj IA, D'Alessio PA, Rangan P, Agarwal SK, Tinta NC, Martinez BK, Ziadat DS, Yerondopoulos MJ, Kobic E, Kane-Gill SL. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study. J Crit Care. 2022 Feb;67:134-140. doi: 10.1016/j.jcrc.2021.10.018. Epub 2021 Nov 09. PMID: 34768175.
Copy Download .nbib Format: NLM
Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

Journal of cardiovascular pharmacology and therapeutics

Moreland-Head LN, Coons JC, Seybert AL, Gray MP, Kane-Gill SL.
PMID: 33403858
J Cardiovasc Pharmacol Ther. 2021 Jul;26(4):341-348. doi: 10.1177/1074248420984082. Epub 2021 Jan 06.

INTRODUCTION: Drug-induced QTPURPOSE: The objective of this study is to determine the drugs reported to be associated with arrhythmias other than QTMETHODS: FAERS reports from 2004 quarter 1 through 2019 quarter 1 were combined to create a dataset of...

Cite
Moreland-Head LN, Coons JC, Seybert AL, et al. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. J Cardiovasc Pharmacol Ther. 2021;26(4):341-348doi: 10.1177/1074248420984082.
Moreland-Head, L. N., Coons, J. C., Seybert, A. L., Gray, M. P., & Kane-Gill, S. L. (2021). Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Journal of cardiovascular pharmacology and therapeutics, 26(4), 341-348. https://doi.org/10.1177/1074248420984082
Moreland-Head, Lindsay N, et al. "Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database." Journal of cardiovascular pharmacology and therapeutics vol. 26,4 (2021): 341-348. doi: https://doi.org/10.1177/1074248420984082
Moreland-Head LN, Coons JC, Seybert AL, Gray MP, Kane-Gill SL. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. J Cardiovasc Pharmacol Ther. 2021 Jul;26(4):341-348. doi: 10.1177/1074248420984082. Epub 2021 Jan 06. PMID: 33403858.
Copy Download .nbib Format: NLM
Outcome Assessment of Critical Care Pharmacist Services.

Hospital pharmacy

Bauer SR, Kane-Gill SL.
PMID: 27559182
Hosp Pharm. 2016 Jul;51(7):507-13. doi: 10.1310/hpj5107-507.

No abstract available.

Cite
Bauer SR, Kane-Gill SL. Outcome Assessment of Critical Care Pharmacist Services. Hosp Pharm. 2016;51(7):507-13doi: 10.1310/hpj5107-507.
Bauer, S. R., & Kane-Gill, S. L. (2016). Outcome Assessment of Critical Care Pharmacist Services. Hospital pharmacy, 51(7), 507-13. https://doi.org/10.1310/hpj5107-507
Bauer, Seth R, and Kane-Gill, Sandra L. "Outcome Assessment of Critical Care Pharmacist Services." Hospital pharmacy vol. 51,7 (2016): 507-13. doi: https://doi.org/10.1310/hpj5107-507
Bauer SR, Kane-Gill SL. Outcome Assessment of Critical Care Pharmacist Services. Hosp Pharm. 2016 Jul;51(7):507-13. doi: 10.1310/hpj5107-507. PMID: 27559182; PMCID: PMC4981097.
Copy Download .nbib Format: NLM
Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study.

Chest

Callaway Kim K, Tadrous M, Kane-Gill SL, Barbash IJ, Rothenberger SD, Suda KJ.
PMID: 34389295
Chest. 2021 Dec;160(6):2123-2134. doi: 10.1016/j.chest.2021.08.007. Epub 2021 Aug 11.

BACKGROUND: Drug supply disruptions have increased during the COVID-19 pandemic, especially for medicines used in the ICU. Despite reported shortages in wealthy countries, global analyses of ICU drug purchasing during COVID-19 are limited.RESEARCH QUESTION: Has COVID-19 impacted global drug...

Cite
Callaway Kim K, Tadrous M, Kane-Gill SL, et al. Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study. Chest. 2021;160(6):2123-2134doi: 10.1016/j.chest.2021.08.007.
Callaway Kim, K., Tadrous, M., Kane-Gill, S. L., Barbash, I. J., Rothenberger, S. D., & Suda, K. J. (2021). Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study. Chest, 160(6), 2123-2134. https://doi.org/10.1016/j.chest.2021.08.007
Callaway Kim, Katherine, et al. "Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study." Chest vol. 160,6 (2021): 2123-2134. doi: https://doi.org/10.1016/j.chest.2021.08.007
Callaway Kim K, Tadrous M, Kane-Gill SL, Barbash IJ, Rothenberger SD, Suda KJ. Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study. Chest. 2021 Dec;160(6):2123-2134. doi: 10.1016/j.chest.2021.08.007. Epub 2021 Aug 11. PMID: 34389295; PMCID: PMC8421073.
Copy Download .nbib Format: NLM
AKD-The Time Between AKI and CKD: What Is the Role of the Pharmacist?.

Hospital pharmacy

Kane-Gill SL, Bauer SR.
PMID: 29276234
Hosp Pharm. 2017 Nov;52(10):663-665. doi: 10.1177/0018578717733561. Epub 2017 Sep 27.

No abstract available.

Cite
Kane-Gill SL, Bauer SR. AKD-The Time Between AKI and CKD: What Is the Role of the Pharmacist?. Hosp Pharm. 2017;52(10):663-665doi: 10.1177/0018578717733561.
Kane-Gill, S. L., & Bauer, S. R. (2017). AKD-The Time Between AKI and CKD: What Is the Role of the Pharmacist?. Hospital pharmacy, 52(10), 663-665. https://doi.org/10.1177/0018578717733561
Kane-Gill, Sandra L, and Bauer, Seth R. "AKD-The Time Between AKI and CKD: What Is the Role of the Pharmacist?." Hospital pharmacy vol. 52,10 (2017): 663-665. doi: https://doi.org/10.1177/0018578717733561
Kane-Gill SL, Bauer SR. AKD-The Time Between AKI and CKD: What Is the Role of the Pharmacist?. Hosp Pharm. 2017 Nov;52(10):663-665. doi: 10.1177/0018578717733561. Epub 2017 Sep 27. PMID: 29276234; PMCID: PMC5735753.
Copy Download .nbib Format: NLM
Adverse drug reactions in therapeutic hypothermia after cardiac arrest.

Therapeutic advances in drug safety

Witcher R, Dzierba AL, Kim C, Smithburger PL, Kane-Gill SL.
PMID: 28382198
Ther Adv Drug Saf. 2017 Mar;8(3):101-111. doi: 10.1177/2042098616679813. Epub 2016 Nov 29.

BACKGROUND: Therapeutic hypothermia (TH) improves survival and neurologic function in comatose survivors of cardiac arrest. Many medications used to support TH have altered pharmacokinetics and pharmacodynamics during this treatment. It is unknown if or at what frequency the medications...

Cite
Witcher R, Dzierba AL, Kim C, et al. Adverse drug reactions in therapeutic hypothermia after cardiac arrest. Ther Adv Drug Saf. 2016;8(3):101-111doi: 10.1177/2042098616679813.
Witcher, R., Dzierba, A. L., Kim, C., Smithburger, P. L., & Kane-Gill, S. L. (2017). Adverse drug reactions in therapeutic hypothermia after cardiac arrest. Therapeutic advances in drug safety, 8(3), 101-111. https://doi.org/10.1177/2042098616679813
Witcher, Robert, et al. "Adverse drug reactions in therapeutic hypothermia after cardiac arrest." Therapeutic advances in drug safety vol. 8,3 (2017): 101-111. doi: https://doi.org/10.1177/2042098616679813
Witcher R, Dzierba AL, Kim C, Smithburger PL, Kane-Gill SL. Adverse drug reactions in therapeutic hypothermia after cardiac arrest. Ther Adv Drug Saf. 2017 Mar;8(3):101-111. doi: 10.1177/2042098616679813. Epub 2016 Nov 29. PMID: 28382198; PMCID: PMC5367663.
Copy Download .nbib Format: NLM
Implementation and Assessment of a Pharmacy Educational Program Concerning Laboratory Monitoring for Medications.

The Canadian journal of hospital pharmacy

LeBlanc JM, Cameron-Coffill K, Symes JL, Kane-Gill S, Duplisea K, Mowatt J.
PMID: 28348429
Can J Hosp Pharm. 2017 Jan-Feb;70(1):19-26. doi: 10.4212/cjhp.v70i1.1625. Epub 2017 Feb 28.

BACKGROUND: The pharmacist's role in monitoring medication therapy, including the ability to order laboratory tests as a delegated medical function, has increased dramatically over the past 20 years.OBJECTIVES: To implement and assess the impact of an intervention designed to...

Cite
LeBlanc JM, Cameron-Coffill K, Symes JL, et al. Implementation and Assessment of a Pharmacy Educational Program Concerning Laboratory Monitoring for Medications. Can J Hosp Pharm. 2017;70(1):19-26doi: 10.4212/cjhp.v70i1.1625.
LeBlanc, J. M., Cameron-Coffill, K., Symes, J. L., Kane-Gill, S., Duplisea, K., & Mowatt, J. (2017). Implementation and Assessment of a Pharmacy Educational Program Concerning Laboratory Monitoring for Medications. The Canadian journal of hospital pharmacy, 70(1), 19-26. https://doi.org/10.4212/cjhp.v70i1.1625
LeBlanc, Jaclyn M, et al. "Implementation and Assessment of a Pharmacy Educational Program Concerning Laboratory Monitoring for Medications." The Canadian journal of hospital pharmacy vol. 70,1 (2017): 19-26. doi: https://doi.org/10.4212/cjhp.v70i1.1625
LeBlanc JM, Cameron-Coffill K, Symes JL, Kane-Gill S, Duplisea K, Mowatt J. Implementation and Assessment of a Pharmacy Educational Program Concerning Laboratory Monitoring for Medications. Can J Hosp Pharm. 2017 Jan-Feb;70(1):19-26. doi: 10.4212/cjhp.v70i1.1625. Epub 2017 Feb 28. PMID: 28348429; PMCID: PMC5358054.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 30 entries